Medtronic Deep Brain Stimulation Clinician Programmer Receives FDA Approval
Medtronic announced that the Food and Drug Administration (FDA) had recently approved its Deep Brain Stimulation (DBS) Clinician Programmer and Activa Programming Application. The Activa Programming Application is managed on the Samsung Galaxy Tab S2 Tablet interface and was designed with consideration of input from hundreds of clinicians worldwide. The new system is a more visual application, and even shows representation of the electrodes on the screen. It was designed with the treating neurologist and neurosurgeon in mind to allow a more efficient post-implant treatment process and streamlined workflow.
The programmer also enables the upgrade of the Activa rechargeable implantable neurostimulator service life increase of an additional 6 years for a total of 15 years until the next device replacement. Patients will be able to experience over 66% more time before an additional surgery.
“The Activa Application is much simpler to use and will free up a lot of time for the physician,” said Brett Wall, Sr. Vice President and President, Brain Therapies, Medtronic. “This is the new programming platform that will enable future generations of devices that are designed to adjust the therapy according to what the patient needs. This is the gateway to a technological suite with more options and better solutions for the patient and the practitioner.”
Approximately 125,000 Medtronic Activa devices have been implanted globally. The US launch is anticipated to take place by the end of June, 2018.